NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.

Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.